High serum background binding reduced seropositivity detection in MOG ratio analysis. MOG antibody antibody detection demyelination flow cytometry analysis myelitis optic neuritis (ON) patient diagnosis.Ĭopyright © 2020 Tea, Pilli, Ramanathan, Lopez, Merheb, Lee, Zou, Liyanage, Bassett, Thomsen, Reddel, Barnett, Brown, Dale, Brilot and the Australasian New Zealand MOG Study Group. With increased demand to identify MOG Ab-positive patients, a consensus on analysis is vital to improve patient diagnosis and for cross-study comparisons to ultimately define MOG Ab-associated disorders. Most MOG Ab serostatuses were similar across analyses when optimal thresholds obtained by ROC analyses were used, demonstrating the robust nature and high discriminatory power of flow cytometry cell-based assays. Background binding and MOG ratio value were negatively correlated, in which patients seronegative by MOG ratio had high non-specific binding, a characteristic of serum that must be acknowledged. Loss of seropositivity and reduced detection sensitivity were observed when MOG ratio analyses or when 10 standard deviation (SD) or an arbitrary number was used to establish the threshold.
#Define mog series#
Herein, we used a large cohort of 482 sera including samples from patients with monophasic or relapsing demyelination phenotypes consistent with MOG antibody-associated demyelination and other neurological diseases, as well as healthy controls, and applied a series of published analyses involving a background subtraction (delta) or a division (ratio). However, there is currently no consensus on data analysis for example, seropositive thresholds have been reported using varying standard deviations above a control cohort. Flow cytometry, in which serum binding to MOG-expressing cells and control cells are quantitively evaluated, is a widely used observer-independent, precise, and reliable detection method.
Live cell-based assays that detect MOG Ab against conformational MOG are currently the gold standard.
Human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have become a useful clinical biomarker for the diagnosis of a spectrum of inflammatory demyelinating disorders.
0 kommentar(er)
